car20.19.22 cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2022 (NCT05094206)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
- CD22Immunity, passive
CD22 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06879340 | Phase 1 | Mar 31, 2025 | University of Kansas |
| NCT05094206 | Phase 1 | Feb 28, 2022 | Medical College of Wisconsin |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Kansas | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1